Advertisement
Table 1 Baseline characteristics of patients
| n = 27 | |
|---|---|
| Age (yrs) | 61.6 ± 10.0 |
| Woman (n,%) | 15 (56) |
| Median disease duration (yrs, p25-p75) | 11.2 (4.2- 17.4) |
| Median number of previous DMARDs (n) | 2.5 (2.0- 3.3) |
| Previously treated with another biological (n, %) | 3 (11%) |
| Rheumatoid factor positive (n,%) | 21 (78) |
| Duration of infliximab therapy (yrs) | 3.7 ± 2.3 |
| Interval infliximab infusions (wks) | 6.8 ± 2.0 |
| Disease Activity at baseline | |
| Remission (n,%) | 7 (26) |
| Low disease activity (n,%) | 6 (22) |
| Moderate disease activity (n,%) | 11 (41) |
| High disease activity (n,%) | 3 (11) |
| DMARD at baseline (n,%) | 23 (85) |
| Methotrexate (n,%) | 17 (63) |
| Dose (mg/week) | 16.8 ± 5.5 |
| Azathioprine (n,%) | 4 (15%) |
| Prednisone at baseline (n, %) | 5 (19%) |
| Dose (mg/day) | 5.8 ± 1.8 |
